摘要
当前,全球约有1.5亿慢性HCV感染者,其中20%会进展为肝硬化并最终死于终末期肝病和肝癌。干扰素(IFN)长期作为慢性丙型肝炎治疗的基石,在维持持续病毒学应答以及阻止病情进展方面有重要作用,但其疗效有限、不良反应多。近年来,直接抗病毒药物(DAAs)呈现出良好的疗效,在DAAs的基础上,介绍了无IFN抗HCV方案的最新研究进展,认为随着DAAs的出现,无IFN抗HCV方案发展迅速,前景较好。
There are about 150 million people around the world with chronic hepatitis C virus （HCV） infection currently, of whom 20% will ultimately progress to cirrhosis and eventually die of end - stage liver disease and hepatocellular carcinoma. Interferon （ IFN ） has long been recognized as the cornerstone of the treatment of chronic hepatitis C because of its role in sustained virologic response and prevention of disease progression. However, it has limited efficacy and multiple adverse effects. In recent years, direct- acting antiviral agents （DAAs） have shown good efficacy. This review summarizes the recent advances in IFN - free anti - HCV therapeutic regimens based on DAAs. We believe that, with the emergence of DAAs ; IFN - free therapies will develop rapidly and display better prospects.
出处
《临床肝胆病杂志》
CAS
2016年第1期169-173,共5页
Journal of Clinical Hepatology
基金
上海市科委"科技创新行动计划"医学与农业领域重点项目(13401902100)
上海市卫生局临床医学应用研究项目(20114279)
关键词
肝炎
丙型
慢性
抗病毒药
蛋白酶抑制药
综述
hepatitis C, chronic
antiviral agents
protease inhibitors
review
